Victory Capital Management
CYTK icon

Victory Capital Management’s Cytokinetics CYTK Stock Holding History

Victory Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7M Buy
19,929
+651
+3% +$46.7K ﹤0.01% 1681
2026
Q1 		$1.27M Buy
19,278
+1,735
+10% +$110K ﹤0.01% 1747
2025
Q4 		$1.11M Sell
17,543
-92
-0.5% -$5.72K ﹤0.01% 1785
2025
Q3 		$969K Sell
17,635
-20,479
-54% -$844K ﹤0.01% 1855
2025
Q2 		$1.26M Buy
38,114
+16,538
+77% +$575K ﹤0.01% 1742
2025
Q1 		$867K Sell
21,576
-140
-0.6% -$6.43K ﹤0.01% 1868
2024
Q4 		$1.02M Sell
21,716
-13,888
-39% -$721K ﹤0.01% 1801
2024
Q3 		$1.88M Sell
35,604
-1,435
-4% -$80K ﹤0.01% 1501
2024
Q2 		$2.01M Buy
37,039
+3,436
+10% +$207K ﹤0.01% 1442
2024
Q1 		$2.36M Sell
33,603
-158,051
-82% -$12.2M ﹤0.01% 1410
2023
Q4 		$16M Buy
191,654
+174,848
+1,040% +$6.33M 0.02% 863
2023
Q3 		$495K Buy
16,806
+1,091
+7% +$36.3K ﹤0.01% 1994
2023
Q2 		$513K Buy
15,715
+320
+2% +$11.8K ﹤0.01% 1972
2023
Q1 		$542K Sell
15,395
-70,037
-82% -$2.86M ﹤0.01% 1972
2022
Q4 		$3.91M Sell
85,432
-513,796
-86% -$22.1M ﹤0.01% 1255
2022
Q3 		$29M Buy
599,228
+523,279
+689% +$25.2M 0.03% 655
2022
Q2 		$2.98M Buy
75,949
+52,886
+229% +$2.13M ﹤0.01% 1361
2022
Q1 		$920K Buy
23,063
+14,398
+166% +$512K ﹤0.01% 1850
2021
Q4 		$395K Sell
8,665
-1,106
-11% -$42.7K ﹤0.01% 2281
2021
Q3 		$349K Buy
+9,771
New +$288K ﹤0.01% 2332
2021
Q2 		– Sell
-9,933
Closed -$231K – 2766
2021
Q1 		$231K Buy
+9,933
New +$212K ﹤0.01% 2486
2020
Q2 		– Sell
-8,085
Closed -$95K – 2706
2020
Q1 		$95K Sell
8,085
-3,286
-29% -$41.9K ﹤0.01% 2329
2019
Q4 		$121K Buy
11,371
+3,057
+37% +$31.4K ﹤0.01% 2480
2019
Q3 		$95K Buy
+8,314
New +$104K ﹤0.01% 2454

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Victory Capital Management's CYTK Position: Q2 2026 in Review

Victory Capital Management increased its Cytokinetics (CYTK) stake by 3.4% in Q2 2026, buying an estimated $46.7K and bringing the position to 19,929 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1681.

Victory Capital Management first reported a position in CYTK in Q3 2019 and has held it in 24 quarters since. The position peaked at $29M in Q3 2022. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Victory Capital Management held 19,929 shares of Cytokinetics worth $1.7M as of Q2 2026.
  • Victory Capital Management bought 651 Cytokinetics shares in Q2 2026, an estimated $46.7K.
  • Cytokinetics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1681 holding.
  • Victory Capital Management first reported a position in Cytokinetics in Q3 2019 and has held it in 24 quarters since.
  • Victory Capital Management's Cytokinetics position peaked at $29M in Q3 2022.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.